Cirrhosis, Liver, Kidney Injury, Variceal Hemorrhage
Conditions
Brief summary
Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.
Interventions
DRUGTerlipressin
Continuous or intermittent intravenous infusion of terlipressin was given.
DRUGSomatostatin
Continuous or intermittent intravenous infusion of somatostatin was given.
DRUGOctreotide
Continuous or intermittent intravenous infusion of octreotide was given.
Sponsors
General Hospital of Shenyang Military Region
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Cirrhotic patients who were admitted between January 2010 and December 2018. 2. A diagnosis of acute gastrointestinal bleeding. 3. Patients who received terlipressin or somatostatin/octreotide. 4. Age or sex was not limited. 5. Use of endoscopy was not limited. 6. Comorbidity was not limited. 7. Malignancy was not limited.
Exclusion criteria
1. Renal parenchymal diseases. 2. Absence of baseline serum creatinine. 3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide. 4. Duration of terlipressin or somatostatin/octreotide was less 3 days. 5. Patients who underwent transjugular intrahepatic portosystemic shunt. 6. Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding | Through study completion, an average of 1-2 weeks | ICA-AKI and kidney function damage |
| Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding | Through study completion, an average of 1-2 weeks | In-hospital mortality |
| Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage | Through study completion, an average of 1-2 weeks | In-hospital mortality associated with ICA-AKI and kidney function damage |
Countries
China
Outcome results
None listed